S&P Futures
4,268.50 -18.00 (-0.42%) Dow Futures
33,879.00 -102.00 (-0.30%) Nasdaq Futures
13,453.75 -69.50 (-0.51%) Russell 2000 Futures
1,990.30 -11.40 (-0.57%) Crude Oil
89.79 -0.71 (-0.78%) Gold
1,769.80 -1.40 (-0.08%)
Personalis, Inc. (PSNL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.4800 |
| Open | 4.5100 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 1000 |
| Day's Range | 4.1800 - 4.5800 |
| 52 Week Range | 3.1300 - 23.0400 |
| Volume | |
| Avg. Volume | 655,800 |
| Market Cap | 197.497M |
| Beta (5Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3760 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.60 |
- Business Wire
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
MENLO PARK, Calif., August 17, 2022--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics. The amended complaint asserts a newly-issued patent in Personalis’ growing intellectual property portfolio relating to detection of molecular residual disease (MRD).
- Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., August 16, 2022--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that, effective on August 15, 2022, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of its common stock to two new employees under Personalis’ 2020 Inducement Plan.
- Business Wire
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
MENLO PARK, Calif. & VANCOUVER, British Columbia, August 15, 2022--Personalis in partnership with BC Cancer to assess clinical and economic benefits of ctDNA for colorectal and pancreatic cancers
